Clinical trials: Throat Carcinoma
Nasopharyngeal Carcinoma
Intensity-modulated Radiation Therapy Combined With Cisplatin or Nedaplatin Chemotherapy in Nasopharyngeal Carcinoma
This phase II trial is studying cisplatin or nedaplatin combine with IMRT to evaluate which one is better efficacy and security in nasopharyngeal carcinoma.
- Trial name
- NCT01265147
- Testing
- Cisplatin, Nedaplatin
- Where
- China
- Volunteers
- 20 people
- Sponsor
- Daping Hospital and the Research Institute of Surgery of the Third Military Medical University
Nasopharyngeal Carcinoma
Pembrolizumab for Nasopharyngeal Carcinoma Patients With Detectable Plasma Epstein-Barr Virus DNA
This is a single-arm, multi-center, open-label, phase II trial to examine the efficacy of pembrolizumab for prolonging the one-year disease free survival in nasopharyngeal carcinoma patients with solely detectable EBV DNA after…
- Trial name
- NCT03544099
- Testing
- Pembrolizumab
- Where
- 8 sites in Taiwan
- Volunteers
- 2 people
- Sponsor
- National Health Research Institutes, Taiwan
Squamous Cell Carcinoma of Head and Neck, Squamous Cell Carcinoma of Head and Neck (SCCHN)
TMV Vaccine Alone or With Toripalimab-tpzi for Recurrent Head and Neck Squamous Cell Carcinoma
The goal of this clinical trial is to learn if an experimental, personalized cancer vaccine called TMV vaccine is safe and to find the best dose to study in future trials.
- Conditions
- Squamous Cell Carcinoma of Head and Neck, Squamous Cell Carcinoma of Head and Neck (SCCHN), HNSCC, Neoplasm Recurrence, Local
- Trial name
- NCT07898124
- Testing
- TMV Vaccine, Toripalimab-tpzi
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- Metaclipse Therapeutics Corporation
Head Neck Cancer, Mouth Cancer
CApecitabine Prior to TUmor Resection in Ent Oncology (CAPTURE)
head and neck squamous cell carcinoma (HNSCC) is a type of cancer that affects areas such as the mouth, throat, and voice box. Despite medical progress, little has changed in the care for patients with HPV-negative cancer.
- Conditions
- Head Neck Cancer, Mouth Cancer, Throat Cancer, Larynx Cancer
- Trial name
- CAPTURE (NCT07254962)
- Testing
- Capecitabine, Standard of Care (SOC)
- Volunteers
- 75 people
- Sponsor
- Sir Mortimer B. Davis - Jewish General Hospital
Oropharyngeal Cancer, Human Papillomavirus-Related Carcinoma
Molecular Signatures of HPV+ ORL Cancers (OROPAP)
The aim of this study is to identify HPV molecular signature in head and neck cancer to establish a new classification for positive human papillomavirus oropharyngeal tumor
- Trial name
- OROPAP (NCT04189003)
- Where
- France
- Volunteers
- 66 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Nasopharyngeal Carcinoma, Recurrent Cancer
Tranilast as a Radiosensitizer in Reradiation of Nasopharyngeal Carcinoma
Nasopharyngeal carcinoma is one of the high incidence head and neck cancer in Southeast Asia. Radiotherapy is the main treatment for nasopharyngeal carcinoma, and its response rate can reach 80~90%.
- Trial name
- NCT05626829
- Testing
- Tranilast
- Where
- China
- Volunteers
- 18 people
- Sponsor
- Jian Guan
Nasopharyngeal Carcinoma, Hepatocellular Carcinoma
A Study of Adoptive Immunotherapy With Autologous Tumor Infiltrating Lymphocytes in Solid Tumors
Background: T cell based adoptive immunotherapy including CTL and TIL may stimulated the immune system and stop cancer cells from growing.
- Conditions
- Nasopharyngeal Carcinoma, Hepatocellular Carcinoma, Breast Carcinoma
- Trial name
- NCT01462903
- Testing
- tumor infiltrating lymphocytes, IL-2
- Where
- 2 sites in China
- Volunteers
- 20 people
- Sponsor
- Sun Yat-sen University
Cancer Survivor, Dysphagia
Manual Therapy in Treating Fibrosis-Related Late Effect Dysphagia in Head and Neck Cancer Survivors
This trial studies how well manual therapy works in treating fibrosis-related late effect dysphagia in head and neck cancer survivors.
- Conditions
- Cancer Survivor, Dysphagia, Fibrosis, Head and Neck Carcinoma
- Trial name
- MANTLE (NCT03612531)
- Testing
- Manual Therapy
- Where
- United States
- Volunteers
- 26 people
- Sponsor
- M.D. Anderson Cancer Center
Nasopharyngeal Carcinoma, PD-1 Inhibitors
PD-1 Inhibitors Plus Chemoradiotherapy for Metastatic Nasopharyngeal Carcinoma: an Open-label Single-arm, Phase II Trial
programmed cell death-1 (PD-1) inhibitors has been recommended as the first-line treatment for recurrent/metastatic nasopharyngeal carcinoma (R/M NPC), but progression-free survival (PFS) and overall survival (OS) was still…
- Conditions
- Nasopharyngeal Carcinoma, PD-1 Inhibitors, Chemoradiotherapy
- Trial name
- NCT05520814
- Testing
- PD-1 inhibitors, chemoradiotherapy
- Where
- China
- Volunteers
- 50 people
- Sponsor
- Sichuan Cancer Hospital and Research Institute
Cisplatin, Carboplatin
Cisplatin-based and Carboplatin-based Chemoradiation in Locoregionally Advanced Nasopharyngeal Carcinoma
The purpose of this study is to compare cisplatin-based with carboplatin-based chemoradiotherapy in patients with locoregionally advanced nasopharyngeal carcinoma (NPC), in order to confirm the value of carboplatin-based…
- Conditions
- Cisplatin, Carboplatin, NPC
- Trial name
- NCT03919552
- Testing
- Docetaxel,Carboplatin, Docetaxel,Cisplatin, Carboplatin-based concurrent chemoradiotherapy
- Where
- China
- Volunteers
- 482 people
- Sponsor
- Nanfang Hospital, Southern Medical University
Nasopharyngeal Carcinoma (NPC), Osteoradionecrosis of the Jaw
Impacted Tooth Management and Osteoradionecrosis Risk in NPC
This multicenter, randomized controlled trial is designed to determine whether omitting prophylactic extraction of impacted teeth before radiotherapy leads to an unacceptably higher risk of jaw osteoradionecrosis (JORN) compared…
- Trial name
- NCT07764887
- Testing
- Omission of Prophylactic Impacted Tooth Extraction, Prophylactic Impacted Tooth Extraction
- Where
- 11 sites in China
- Volunteers
- 536 people
- Sponsor
- First Affiliated Hospital of Guangxi Medical University
Nasopharyngeal Carcinoma
Nituzumab (Taixinsheng ®） A Prospective, Randomized, Double-blind, Placebo-controlled, Multicenter Phase II Clinical Study on the Efficacy and Safety of Combined Induction Chemotherapy for Locally Advanced Nasopharyngeal Carcinomatreatment of Locally Advanced Nasopharyngeal Carcinoma
Nasopharyngeal carcinoma (NPC) is a head and neck tumor. Studies have shown that more than 70% of patients are diagnosed with locally advanced nasopharyngeal carcinoma at the time of initial diagnosis.
- Trial name
- NCT05508347
- Where
- China
- Volunteers
- 170 people
- Sponsor
- Sichuan Cancer Hospital and Research Institute
Locally Advanced Oral Squamous Cell Carcinoma, Locally Advanced Oropharyngeal Squamous Cell Carcinoma
Impact of Postoperative Radiotherapy Versus PD-1 Inhibitor Maintenance on Survival in Resectable Locally Advanced Oral and Oropharyngeal Squamous Cell Carcinoma
Neoadjuvant immunochemotherapy (NAIC) has demonstrated promising pathological and survival outcomes in patients with resectable locally advanced oral and oropharyngeal squamous cell carcinoma (LA-OSCC/OPSCC).
- Trial name
- NCT07457099
- Testing
- Observation, Postoperative Radiotherapy, PD-1 Inhibitor Maintenance Therapy
- Where
- China
- Volunteers
- 85 people
- Sponsor
- Zhujiang Hospital
Nasopharyngeal Cancinoma (NPC)
EBV Lytic Reactivation Therapy Combined With PD-1 Antibody in Recurrent/Metastatic Nasopharyngeal Carcinoma
Nearly all undifferentiated nasopharyngeal carcinoma (NPC) are associated with the Epstein-Barr Virus (EBV), which typically remains in a latent, non-immunogenic state within tumor cells.
- Trial name
- NCT07138989
- Testing
- Valganciclovir Hydrochloride Tablets, gemcitabine, cisplatin, and PD-1 antibody
- Where
- China
- Volunteers
- 10 people
- Sponsor
- Sun Yat-sen University
Nasopharyngeal Cancer
Dendritic Cell Therapy With CD137L-DC-EBV-VAX in Locally Advanced Stage IV or Locally Recurrent/Metastatic Nasopharyngeal Carcinoma
This study is carried out to find out the safety and recommended dose of CD137L-DC-EBV-VAX in nasopharyngeal cancer. CD137L-DC-EBV-VAX is a product made from one of our own immune system cells (dendritic cell, DC).
- Trial name
- NCT03282617
- Testing
- CD137L-DC-EBV-VAX
- Where
- Singapore
- Volunteers
- 55 people
- Sponsor
- National University Hospital, Singapore
Nasopharyngeal Carcinoma
PD-L1 and BRAF Expression in Nasopharyngeal Carcinoma
The prognostic value of programmed death-ligand 1 (PD-L1) and BRAF expression in nasopharyngeal carcinoma (NPC) is not well-defined.
- Trial name
- NCT03989297
- Testing
- Radiation
- Where
- China
- Volunteers
- 104 people
- Sponsor
- Kiang Wu Hospital
Nasopharyngeal Carcinoma
Induction Gemcitabine and Cisplatin in Patients With Locoregionally Advanced Nasopharyngeal Carcinoma
The purpose of this study is to compare induction chemotherapy (gemcitabine+cisplatin) plus concurrent chemoradiotherapy (CCRT) with CCRT alone in patients with locoregionally advanced nasopharyngeal carcinoma(NPC), in order to…
- Trial name
- NCT01872962
- Testing
- gemcitabine and cisplatin (Induction chemotherapy), IMRT and concurrent cisplatin
- Where
- China
- Volunteers
- 480 people
- Sponsor
- Sun Yat-sen University
Nasopharyngeal Carcinoma, Squamous Cell Carcinoma of the Head and Neck
The Diagnosis of NPC Using the Probe-based Confocal Laser Endomicroscopy
To evaluate the use of probe-based confocal laser endomicroscopy (pCLE) in human nasopharyngeal mucosa for the differentiation of the nasopharyngeal squamous cell carcinomas.
- Trial name
- NCT03202173
- Testing
- 10% fluorescein
- Where
- China
- Volunteers
- 31 people
- Sponsor
- Eye & ENT Hospital of Fudan University
Nasopharyngeal Carcinoma
Immune Score Based Radiomics in Nasopharyngeal Carcinoma
In nasopharyngeal carcinoma (NPC), tumor, node and metastasis (TNM) staging system is the main tool for determining treatment strategy and assessment of prognosis.
- Trial name
- NCT05126160
- Testing
- Immune Score Based Radiomics
- Where
- 5 sites in China
- Volunteers
- 494 people
- Sponsor
- Zhejiang Cancer Hospital
Nasopharyngeal Carcinoma
Serial Plasma EBV DNA for Nasopharyngeal Carcinoma
Nasopharyngeal carcinoma (NPC) is an endemic malignancy in Southern China, Hong Kong, Taiwan, Singapore and Malaysia. It is highly associated with Epstein-Barr virus (EBV).
- Trial name
- NCT02476669
- Where
- Hong Kong
- Volunteers
- 900 people
- Sponsor
- The University of Hong Kong
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.